🌟 And the winner is…. Androgen receptor pathway inhibitors (ARPI) for referring to the drugs abiraterone, apalutamide, enzalutamide & darolutamide. Standardizing terminology can reduce confusion from all different terms used in the literature #APCCC24

Umberto Capitanio Stacy Loeb, MD Advanced Prostate Cancer Consensus Conference We did discuss how DRE very actively frightens men away from getting a prostate checkup. Quite alarming data. DRE may therefore cause more harm. Plus see the sys review from Shahrokh F. Shariat and Probase data, both in European Urology Oncology, showing how useless DRE is in primary care/screening

ENZA-p trial The Lancet Oncology
authors.elsevier.com/a/1iw3e5EIIgPd…
Enzalutamide + adaptive-dosed (2 or 4) 177 Lu-PSMA617 vs enza alone in mCRPC.
Biomarker guided combination therapy works!
Better response depth/duration with no added tox. ANZUP NHMRC CTC Movember Australia St Vincent's Sydney

🚨 Breaking results 🚨 PRIME Trial UCL study presented at #EAU24 European Association of Urology (EAU). This 🌍 multicentre trial (n=555, 22 sites) showed that biparametric MRI without contrast is non-inferior 2 multiparametric MRI & should be the new standard for prostate cancer diagnosis if image quality is good

8 yrs after our first paper, validation in >350,000 cancers across multiple ethnicities/age groups 🇬🇧🇺🇸🇸🇪🇸🇬 & 3 yrs after NICE adoption- The Cambridge Prognostic Groups is in the EAU prostate cancer guidelines! 🙏🏾 European Association of Urology (EAU), now just one step more & replace 'risk' with prognosis!

Prime study NIXON URBAIN Daniele wonderful presentation by ⁦Veeru Kasi⁩. DCE sequences not needed in the setting of primary biopsy. Great news!

🥁 Ladies and Gentlemen 📣
🔥 PRECISE V2 🔥
🔓Open Access:
tinyurl.com/23fu2bw3

Reassuring data: very low risk of grade inflation/overtreatment induced by MRI-targeting. Congrats Michael and thanks to all co-authors for this collaborative work Romain Diamand Gaelle Fiard Thierry Roumeguere sciencedirect.com/science/articl…

New ESMO - Eur. Oncology guidlines for advanced bladder cancer Annals of Oncology. Enforumab Vedotin & pembro is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant. Gem/cis/nivo or maintenance avelumab for pts where EVP not available annalsofoncology.org/article/S0923-…

I am very happy to share this updated collaborative effort! PSMA-PET–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study sciencedirect.com/science/articl…

In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment. Full trial results: nej.md/49ViJEe

First Lead-212 (Pb-212) in human images - quite remarkable that Alpha emission can be imaged with this quality. Dave Pattison AdvanCell Isotopes #PSMA

jnm.snmjournals.org/content/early/…

Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy jnm.snmjournals.org/content/65/3/3…

In patients with complicated urinary tract infection, clinical and microbiologic treatment success was significantly better with cefepime–taniborbactam (β-lactam and β-lactamase inhibitor) than with meropenem. Read the full CERTAIN-1 trial results: nej.md/3uxZVvK

In the #PSMA #PETimaging arm of the randomized PSMA-SRT trial UCLA and UC San Francisco, M1 disease was detected in ~10% and there was 18% more treatment escalation than in the control arm. Will this lead to improved PSA outcomes? Analysis is planned for 2025.
sciencedirect.com/science/articl…

Weekly Highlight: Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial

buff.ly/40TsHCV

Boris Hadaschik Jan Philipp Radtke Nina Harke

#UroSoMe #Medtwitter #ProstateCancer

The #NEPI Trial: A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in pts with very HR #ProstateCancer who are candidates for radical prostatectomy. Presented by Ulrich Krafft > bit.ly/48Y5p24 Zach Klaassen

It’s hard not to reconsider the activity of ipi/nivo in the good risk population (HR0.82). It now seems to be at least as good as other options and the crossing of the curves is interesting. I’d like to stop using IMDC to determine choice of therapy Daniel Heng #Gu24

After seeing KN564 positive OS for adjuvant pembro presented at #ascogu24 where do you consider adjuvant pembrolizumab for post nephrectomy pts? Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Rana McKay Moshe Ornstein MD Brian Rini, MD Uromigos Tom Powles

The amount of pattern 3 is not predictive of risk in grade group 2 to 4 prostate cancer. So why do current treatment algorithms take into account the amount of pattern 3? (e.g. 3+4 vs. 4+3 disease) sciencedirect.com/science/articl…